Corcept Therapeutics Inc
CORT
View Detailed Chart
37.500USD
+0.970+2.66%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
3.94BMarket Cap
36.71P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.66%
5 Days
-1.83%
1 Month
-56.96%
6 Months
-47.92%
Year to Date
+7.76%
1 Year
-24.77%
View Detailed Chart
TradingKey Stock Score of Corcept Therapeutics Inc
Currency: USD Updated: 2026-01-09Key Insights
Corcept Therapeutics Inc's fundamentals are relatively very healthy, with low ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 88 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 91.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Corcept Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Corcept Therapeutics Inc Highlights
StrengthsRisks
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 67.98% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 675.04M.
Fairly Valued
The company’s latest PE is 36.71, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.27M shares, decreasing 10.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 499.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.34.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
91.000
Target Price
+160.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Corcept Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Corcept Therapeutics Inc Info
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Ticker SymbolCORT
CompanyCorcept Therapeutics Inc
CEOBelanoff (Joseph K)
Websitehttps://www.corcept.com/
FAQs
What is the current price of Corcept Therapeutics Inc (CORT)?
The current price of Corcept Therapeutics Inc (CORT) is 37.500.
What is the symbol of Corcept Therapeutics Inc?
The ticker symbol of Corcept Therapeutics Inc is CORT.
What is the 52-week high of Corcept Therapeutics Inc?
The 52-week high of Corcept Therapeutics Inc is 117.330.
What is the 52-week low of Corcept Therapeutics Inc?
The 52-week low of Corcept Therapeutics Inc is 32.991.
What is the market capitalization of Corcept Therapeutics Inc?
The market capitalization of Corcept Therapeutics Inc is 3.94B.
What is the net income of Corcept Therapeutics Inc?
The net income of Corcept Therapeutics Inc is 141.21M.
Is Corcept Therapeutics Inc (CORT) currently rated as Buy, Hold, or Sell?
According to analysts, Corcept Therapeutics Inc (CORT) has an overall rating of Hold, with a price target of 91.000.
What is the Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT)?
The Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT) is 1.022.
Related Instruments
-1.99%
-0.66%
-1.74%
+0.68%
-0.43%
+0.06%
+2.56%
-1.21%
+0.36%
+0.75%
+1.87%
-1.24%
-0.07%
+0.34%
+0.18%
-1.29%
-0.56%
0.00%
+0.25%
-0.28%
